GNLX earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -3.36. Updated 2026-07-23.
Genelux (GNLX) Research Hub
Genelux (GNLX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.49 USD (-1.19%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.36, market cap 0.11B. This hub links to the full technical, earnings and options research available for GNLX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.49 USD (-1.19%) |
| 52-week range | 2.39 USD – 3.18 USD |
| Trend regime | Range |
| 14-day RSI | 36.1 (Bearish) |
| Trailing P/E | -3.36 |
| Market cap | 0.11B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for GNLX
Covered Call on GNLX: how it works, illustrative setup around the real 2.49 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GNLX: how it works, illustrative setup around the real 2.49 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GNLX: how it works, illustrative setup around the real 2.49 USD price, max profit/loss, breakeven and when to use it. Educational.
GNLX technical analysis: range, last 2.49 USD, RSI 36.1, 52w range 2.39 USD–3.18 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is GNLX in?
Genelux (GNLX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GNLX in an uptrend or downtrend?
As of 2026-09-11, GNLX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GNLX's trailing P/E ratio?
GNLX's trailing P/E is -3.36, with a market cap of 0.11B. See the earnings research page for full valuation detail.
When does GNLX next report earnings?
GNLX is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.2 USD.